SVP, Finance & CAO

Chief Technical Ops Officer

PRESIDENT AND CFO

CHIEF EXECUTIVE OFFICER

Chief Medical Officer

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Institution	Shares	Value	Change
FMR	20,852,907	$1.2B	INCREASED
Jupiter Topco	17,965,847	$1.0B	NEW
T. Rowe Price	15,196,449	$883M	INCREASED
Vanguard	14,092,912	$819M	INCREASED
BlackRock	12,068,129	$702M	INCREASED

Insider	Type	Shares	Value	Date
Elvia Cowan (SVP, Finance & CAO)	TAX-W	1,327	$80K	2026-09-08
Harpreet S. Dhaliwal (Chief Technical Ops Officer)	TAX-W	7,651	$462K	2026-09-08
Andrew Guggenhime (PRESIDENT AND CFO)	TAX-W	7,155	$432K	2026-09-08
Grant Pickering (CHIEF EXECUTIVE OFFICER)	TAX-W	17,056	$1M	2026-09-08
Luis Jodar (Chief Medical Officer)	AWARD	88,254	$5M	2026-09-04

Member	Type	Amount	Date
Gilbert Cisneros (Democrat)	PURCHASE	$1,001 - $15,000	2026-07-16
Gilbert Cisneros (Democrat)	PURCHASE	$1,001 - $15,000	2026-07-15

Vaxcyte, Inc. Common Stock (PCVX) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades

Recent Congressional Trades